Pralatrexate‐based therapy induced response in an adolescent with refractory hepatosplenic T‐cell lymphoma

Dhir, Aditi; Hill, Benjamin C.; Waite, Emily; Cairo, Mitchell S.; Xavier, Ana C.

doi:10.1002/pbc.28460

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

2021

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly treatment of mice with tazemetostat reduced disease burden and significantly prolonged their survival in this aggressive mouse model [35 && ]. New drugs such as pralalexate, have been investigated in HSTCL and reported to be effective [36].…”

Section: Discussionmentioning

confidence: 99%

Hepatosplenic T-cell lymphoma: treatment challenges

Bron

Leval

Michiels

et al. 2021

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewHepatosplenic lymphoma (HSTCL) is a rare T-cell malignancy occurring in young males, associated with immune deficiency in 20% of the cases which, despite aggressive treatments, has a poor survival. Specific recommendations for first-line treatment remain debatable. Recent findingsPublished data covering case reports or series of HSTCL concur that allogeneic stem cell transplant should be proposed as a consolidation after response to chemotherapy in all patients eligible for transplant. In the light of two recent clinical examples, we also confirm that specific chemotherapy and a first-line consolidation with allogeneic transplantation when a donor is available to represent a treatment of choice these rare and distinctive lymphomas. Recent molecular studies are summarized in this review and suggest potential targets for new therapeutic strategies.

show abstract

Section: Discussionmentioning

confidence: 99%